Combivent UDV

Combivent UDV

ipratropium bromide + salbutamol

Manufacturer:

Boehringer Ingelheim

Distributor:

Metro Drug
Concise Prescribing Info
Contents
Ipratropium Br 500 mcg, salbutamol 2.5 mg
Indications/Uses
Management of reversible bronchospasm associated w/ obstructive airway diseases in patients who require more than a single bronchodilator.
Dosage/Direction for Use
Start w/ lowest recommended dose 1 vial. In severe cases, 2 vial may be required for symptom relief. Administration should be stopped when sufficient symptom relief is achieved. Nebulization Adult & childn >12 yr 1 vial every 6-8 hr. Childn 2-12 yr 3 drops/kg/dose (max: 2,500 mcg of salbutamol) every 6-8 hr. Treatment of acute attacks 1 vial for prompt symptom relief. May administer 2nd vial if an attack has not been relieved by 1 vial. Maintenance treatment 1 vial tid-qid.
Contraindications
Hypersensitivity to atropine or its derivatives. Hypertrophic obstructive cardiomyopathy or tachyarrhythmia.
Special Precautions
Hypersensitivity. Discontinue paradoxical bronchospasm immediately & substitute w/ an alternative therapy. Predisposed narrow-angle glaucoma, cystic fibrosis. Insufficiently controlled DM, recent MI, severe organic heart or vascular disorders, hyperthyroidism, pheochromocytoma, risk of narrow-angle glaucoma, prostatic hypertrophy or bladder-neck obstruction. Patients w/ underlying severe heart disease (eg, ischaemic heart disease, arrhythmia, or severe heart failure). Hypokalemia, dyspnoea. May lead to +ve results w/ regards to tests for non-clinical substance abuse eg, doping. Care must be taken not to allow solution or mist into the eyes. May impair ability to drive or operate machinery. Pregnancy & lactation.
Adverse Reactions
headache, throat irritation, cough, dry mouth, GI motility disorders (including constipation, diarrhoea, vomiting) nausea, dizziness.
Drug Interactions
Coadministration w/ other anticholinergic drugs. Increased side effects w/ xanthine derivatives, β-adrenergics & anticholinergics. Increased susceptibility of arrhythmias w/ digoxin. Reduction in bronchodilator effect w/ β-blockers. Enhanced β-adrenergic action w/ MAOIs, TCAs. Increased susceptibility on CV effects of β-agonists w/ halothane, trichloroethylene & enflurane.
MIMS Class
Antiasthmatic & COPD Preparations
ATC Classification
R03AL02 - salbutamol and ipratropium bromide ; Belongs to the class of combination of adrenergics with anticholinergics, that may also include a corticosteroid. Used in the treatment of obstructive airway diseases.
Presentation/Packing
Form
Combivent UDV inhalation soln
Packing/Price
(unit dose vial) 2.5 mL x 20 × 1's (P1,076/box)
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Already a member? Sign in
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Already a member? Sign in